Immunotherapy

• Nivolumab Benefit For MMR-Deficient Patients Extends Past Colorectal Cancer
• Discussion
• Genomic HLA heterozygosity as a predictive marker for survival in lung cancer patients post immunotherapy
• Combined model of frameshift mutations and TMB in predicting response to immunotherapy in NSCLC
• PBRM1 mutation and preliminary response to immune checkpoint blockade treatment in NSCLC
• Data-driven miRNA classifier as response predictor for immune checkpoint inhibitor treatment in advanced-stage cancer patients
• Three-year overall survival update from the PACIFIC trial
• Novel tumour mutation score versus tumour mutation burden in predicting survival after immunotherapy in pan-cancer from MSK-IMPACT cohort
• A novel anti-PD-1 antibody HLX10 study led to the initiation of combination immunotherapy
• Association between immune-related adverse events and efficacy of immune checkpoint inhibitors in patients with advanced hepatocellular carcinoma
• Autologous V gamma 9 V delta 2 T cell therapy to target Epstein Barr Virus (EBV)-related malignancies
• Neoantigen profile of hepatocellular carcinoma reveals its correlation with tumour progression and clonal evolution
• A retrospective analysis of patients with non-small cell lung cancer who developed drug-induced lung disorder by immune checkpoint inhibitors
• High-level expression of HDAC10 is associated with PD-L1 expression and poor prognosis in patients with non-small cell lung cancer receiving pulmon...
• A retrospective analysis of immune checkpoint therapy in patients with non-small cell lung cancer: Focus on thyroid disorder
• Analyse the association between adverse events (AEs) and survival in patients treated with immune checkpoint inhibitors (ICIs)
• Study of searching on efficacy of immune checkpoint inhibitor for the non-small cell lung cancer using FDG-PET/CT and thallium SPECT
• Incidence and characteristic of adrenal insufficiency due to immune checkpoint inhibitors therapy
• PD-L1 profile of nasopharyngeal cancer patients in Indonesia
• Pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for PD-L1-positive advanced non-small cell lung cancer in the real world
• Neutrophil-to-Lymphocyte ratio as a predictive factor for hyperprogressive disease in NSCLC patients treated with immune checkpoint inhibitor
• A new insight into tumour immune-evasion: Crosstalk between cancer stem cells and T regulatory cells
• PACIFIC-5: Phase III study of durvalumab after either concurrent or sequential chemoradiotherapy (CRT) in patients with stage III NSCLC
• A multicenter, randomized, controlled, phase II trial exploring adjuvant combined therapy of apatinib and SHR-1210 (anti-PD-1), in patients with he...
• Hyperprogression after pembrolizumab in recurrent oropharyngeal cancer and the use of nab-paclitaxel as salvage treatment- A case report.

• « Previous
• 1
• 2
• ...
• 92
• Next »